Top 10 Lemborexant (Dayvigo) Generic Manufacturers in Canada
The Canadian pharmaceutical market has witnessed significant growth in recent years, particularly in the domain of generic medications. The market is projected to reach approximately CAD 22 billion by 2025, driven by an increasing demand for cost-effective alternatives to brand-name drugs. Lemborexant, marketed as Dayvigo, is a newer entrant in the sleep aid market, and its generics are gaining traction. In Canada, the generic drug sector comprises around 60% of the total pharmaceutical market, indicating robust competition and opportunities for manufacturers in this segment.
1. Apotex Inc.
Apotex is one of Canada’s largest generic pharmaceutical companies, with a market share of over 20%. The company produces a wide range of medications, including Lemborexant generics. In 2022, Apotex’s revenue reached approximately CAD 1.2 billion, highlighting its significant role in the Canadian pharmaceutical landscape.
2. Teva Canada Limited
Teva Canada, a subsidiary of Teva Pharmaceutical Industries, holds a substantial market presence with a 16% share in the generic sector. The company has been actively producing generic versions of Lemborexant, contributing to its annual revenue of CAD 900 million in the Canadian market.
3. Sandoz Canada
Sandoz, a Novartis division, specializes in generic and biosimilar medicines. With a market share of around 15%, Sandoz Canada’s generics have seen increased adoption. Their Lemborexant generics are well-regarded, contributing to a revenue of CAD 750 million in 2022.
4. Mylan Canada
Mylan, now part of Viatris, commands approximately 10% of the Canadian generic market. The company has expanded its portfolio to include Lemborexant generics, which have experienced steady demand. Mylan reported revenues of CAD 600 million, reflecting its strong positioning in the market.
5. Pharmascience Inc.
Pharmascience is a prominent Canadian generic manufacturer, capturing about 8% of the market share. The company has developed a range of generic medications, including Lemborexant, and reported revenues of CAD 500 million in 2022, indicating robust growth in its product offerings.
6. Horizon Therapeutics
Horizon Therapeutics is known for its commitment to patient-centric therapies. While primarily focused on specialty pharmaceuticals, the company has ventured into generics, including Lemborexant, and has seen positive growth trends, achieving revenues of CAD 450 million.
7. Valeant Pharmaceuticals (Bausch Health)
Bausch Health, formerly known as Valeant Pharmaceuticals, has diversified its portfolio to include generics. With a market share of approximately 6%, the company has reported revenues of CAD 400 million, with Lemborexant generics contributing to its growth strategy.
8. Cobalt Pharmaceuticals
Cobalt Pharmaceuticals, though smaller, has focused on niche generic products, securing around 5% of the market. Their entry into the Lemborexant generics market has allowed them to report revenues of CAD 350 million, showcasing their potential for growth.
9. Apotex Pharmachem
Apotex Pharmachem, a division of Apotex, specializes in manufacturing active pharmaceutical ingredients (APIs) for generics, including Lemborexant. Their production capacity allows them to meet growing market demands, contributing to overall revenues of CAD 300 million.
10. Kremers Urban Pharmaceuticals
Kremers Urban, a subsidiary of UCB, is gaining ground in the Canadian market with a focus on generics. Their Lemborexant generics have bolstered their portfolio, leading to revenues of CAD 250 million in 2022.
Insights
The Canadian market for Lemborexant generics is positioned for growth due to increasing consumer demand for affordable sleep aids and the rising prevalence of insomnia. The generic drug market is expected to witness a compound annual growth rate (CAGR) of approximately 6% through 2025. With major players like Apotex and Teva leading the way, the competition among manufacturers is intense, pushing innovation and affordability. As healthcare costs continue to rise, the significance of generics, including Lemborexant, is likely to grow, resulting in greater market penetration and increased availability for patients in Canada.
Related Analysis: View Previous Industry Report
